Autosomal Recessive Osteopetrosis Type 7 (OPTB7) Caused By Mutations in TNFRSF11A

Autosomal recessive osteopetrosis type 7 (OPTB7) caused by mutations in TNFRSF11A is a very rare, inherited bone disease. It happens when both copies of the TNFRSF11A gene carry harmful changes. This gene makes a protein called RANK that tells early bone-resorbing cells (osteoclasts) to form and work properly. When RANK does not work, osteoclasts are too few or too weak. Old bone is not removed as it should be, so bones become abnormally dense, heavy, and brittle. Dense bone may squeeze nearby nerves and reduce space for bone marrow, causing anemia, infections, and bleeding problems. Signs often begin in infancy and can include poor growth, fractures, vision or hearing problems from nerve compression, and enlarged liver and spleen from bone-marrow failure. This form is sometimes called “osteoclast-poor” osteopetrosis because bone biopsies show very few osteoclasts. NCBI+3MedlinePlus+3PMC+3

ARO7 is a rare, severe bone disease that starts in infancy. The bones become too dense and hard because the body cannot make or activate enough osteoclasts, the cells that normally remove old bone. The problem is a harmful change (mutation) in TNFRSF11A, the gene for the RANK receptor. Without normal RANK signaling, osteoclasts do not form, so old bone is not cleared and new bone fills in poorly. This leads to very dense, brittle bones, bone-marrow crowding (anemia, low platelets), pressure on nerves (vision/hearing loss), enlarged liver/spleen, frequent infections, and sometimes low antibodies (hypogammaglobulinemia). Unlike RANKL (TNFSF11) deficiency, HSCT can restore osteoclasts in ARO7 and is considered curative. MedlinePlus+2PMC+2

Other names

• OPTB7 (OsteoPetrosis, autosomal recessive, type 7)

• TNFRSF11A-related osteopetrosis

• RANK-dependent autosomal recessive osteopetrosis

• Osteoclast-poor osteopetrosis

• In some families, osteopetrosis with hypogammaglobulinemia (low antibody levels) because RANK signaling also touches the immune system. NCBI+3Rare Diseases+3Wiley Online Library+3

Types

Doctors group osteopetrosis by inheritance and severity:

1. Autosomal recessive osteopetrosis (ARO), also called “malignant infantile osteopetrosis,” is the severe, early-onset group that includes type 7 due to TNFRSF11A. It usually starts in the first year of life and can cause bone-marrow failure and nerve compression. MedlinePlus+1

2. Autosomal dominant osteopetrosis (ADO) tends to appear later with milder problems (often fractures and back changes). It is a different genetic group. MedlinePlus

3. Intermediate forms exist between these two ends of the spectrum. The key point is that OPTB7 is a recessive, infant-onset, osteoclast-poor subtype in which bone-marrow transplant does not help because the core problem is a missing RANK signal from non-hematopoietic tissues; transplant replaces marrow cells but cannot fix the signal. NCBI

---

Causes

For a single-gene disease, “causes” are best understood as molecular mechanisms, gene changes, and modifiers that produce the disease picture or make it worse or better.

1. Loss-of-function variants in TNFRSF11A: Pathogenic changes stop RANK from forming or signaling, so osteoclasts cannot develop or work. MedlinePlus+1

2. Missense variants that break RANK signaling: A single amino-acid change can distort the receptor and block the RANKL→RANK signal needed for osteoclast formation. ScienceDirect

3. Nonsense/frameshift variants: Early stop signals create truncated, nonfunctional RANK. ScienceDirect

4. Splice variants: Changes at intron–exon borders disrupt RANK production. ScienceDirect

5. Defective receptor trafficking: Some variants make RANK that cannot reach the cell surface, so it cannot “hear” RANKL. ScienceDirect

6. Failure of osteoclast differentiation: Without RANK, monocyte precursors cannot become osteoclasts (“osteoclast-poor” bone). PMC

7. Failure of osteoclast activation: Even if a few osteoclasts form, they cannot resorb bone well without intact RANK signals. PMC

8. Imbalance in the RANKL–RANK–OPG pathway: The pathway that balances bone breakdown and formation is skewed toward no breakdown. NCBI

9. Consanguinity (same-family parents): Raises the chance a child will inherit two harmful copies in a recessive condition. Rare Diseases

10. Modifier genes in bone remodeling: Variants in other bone genes may worsen or soften the picture. (Inference from pathway data.) PMC

11. Immune pathway cross-talk: RANK signaling overlaps with immune development; immune issues (e.g., low antibodies) may occur and can worsen infections. ScienceDirect

12. Narrowed marrow space: As dense bone fills the marrow cavity, blood-cell production fails, causing anemia and infections; this is a downstream cause of many symptoms. NCBI

13. Cranial base sclerosis: Thick skull base compresses cranial nerves, causing vision and hearing problems. NCBI

14. Hypocalcemia from low bone turnover: Abnormal mineral handling can trigger low calcium and seizures in infants. Rare Diseases

15. Pathologic fractures: Brittle but dense bone breaks easily, driving pain and disability. NCBI

16. Dental and jaw problems: Dense jawbone and poor blood flow raise risks of dental infections and osteomyelitis. Rare Diseases

17. Growth failure: Poor marrow function and repeated illness slow growth. NCBI

18. Recurrent infections: From marrow failure (low white cells) and sometimes low immunoglobulins in TNFRSF11A disease. ScienceDirect

19. Hepatosplenomegaly: The liver and spleen enlarge while trying to make blood cells when marrow space is lost. NCBI

20. Neurologic strain from narrowed foramina: Small skull openings squeeze nerves (optic, facial, auditory). Medscape

---

Common symptoms and signs

1. Poor feeding and poor weight gain in infancy due to early illness burden. Rare Diseases

2. Large head (macrocephaly) and frontal bossing from thick skull bones. Medscape

3. Vision problems (reduced vision, nystagmus) from optic-nerve compression. NCBI

4. Hearing loss from auditory-nerve compression and thick middle-ear bones. NCBI

5. Frequent infections because marrow cannot make enough healthy white cells; in TNFRSF11A disease some children have low antibodies. ScienceDirect

6. Pallor and tiredness from anemia. NCBI

7. Easy bruising or bleeding from low platelets. NCBI

8. Enlarged liver and spleen (hepatosplenomegaly) as the body tries to make blood outside the bone marrow. NCBI

9. Bone pain and irritability from high pressure inside dense bones. NCBI

10. Fractures after minor trauma because dense bone is also brittle. NCBI

11. Short stature and delayed growth from chronic illness and marrow failure. Medscape

12. Dental problems such as delayed tooth eruption, cavities, or jaw infections. Rare Diseases

13. Facial nerve palsy (facial weakness) from nerve compression. NCBI

14. Seizures from low calcium (hypocalcemia) in some infants. Rare Diseases

15. Headaches or vomiting if raised intracranial pressure develops. (General ARO feature tied to skull sclerosis.) NCBI

---

Diagnostic tests

A) Physical examination (bedside observations)

1. General appearance and growth check: Weight, length/height, and head size help spot failure to thrive and macrocephaly in infants with ARO7. Medscape

2. Craniofacial exam: Frontal bossing, wide cranial sutures, and dental eruption delays support the diagnosis. Medscape

3. Neurologic exam of cranial nerves: Vision, facial movement, and hearing can show compression effects early. NCBI

4. Abdominal exam: Palpation for enlarged liver and spleen points toward bone-marrow failure. NCBI

5. Musculoskeletal exam: Bone tenderness, limb deformities, and signs of healed fractures are common in dense, brittle bone disease. NCBI

B) Manual/functional bedside tests

6. Vision screening and fundus exam: Reduced acuity, optic-disc pallor, or papilledema suggest optic-nerve compromise. NCBI

7. Basic hearing tests (Rinne/Weber): Quick bedside checks that can reveal conductive or sensorineural loss; guide formal audiology. Medscape

8. Jaw and dental inspection: Looks for delayed tooth eruption, caries, and signs of jaw infection (osteomyelitis). Rare Diseases

9. Gait and balance assessment: Helps detect effects of fractures, pain, or nerve dysfunction. (General ARO exam step.) NCBI

10. Growth and developmental screening: Charts whether chronic illness is delaying milestones. Medscape

C) Laboratory and pathological tests

11. Complete blood count (CBC): Often shows anemia, low platelets, and sometimes low white cells from reduced marrow space. NCBI

12. Serum chemistries: Calcium, phosphate, alkaline phosphatase, and parathyroid hormone help flag hypocalcemia and abnormal bone turnover. Rare Diseases

13. Immunoglobulin levels: Some TNFRSF11A cases show hypogammaglobulinemia (low antibodies), which increases infection risk. ScienceDirect

14. Bone-marrow aspirate/biopsy: Often hypocellular due to crowded marrow space; helps rule out other marrow diseases. (Supportive in ARO.) NCBI

15. Bone biopsy (when needed): Shows few or absent osteoclasts in osteoclast-poor forms and is considered important for confirming TNFRSF11A/TNFSF11 forms. NCBI

16. Molecular genetic testing: Sequencing TNFRSF11A confirms the exact variant and guides care and genetic counseling. Targeted panels often include other ARO genes (e.g., TCIRG1, CLCN7, OSTM1, SNX10, TNFSF11). PMC+1

D) Electrodiagnostic tests

17. Visual evoked potentials (VEP): Measures signal speed from eye to brain; delayed signals suggest optic-nerve compression. NCBI

18. Brainstem auditory evoked responses (BAER/ABR): Checks hearing-nerve pathways; helpful when infants cannot cooperate with standard tests. NCBI

19. Nerve-conduction studies/EMG: Used when limb weakness, neuropathy, or nerve entrapment from narrowed foramina is suspected. (Supportive in selected cases.) NCBI

E) Imaging tests

20. Skeletal survey X-rays: Classic findings include diffuse osteosclerosis, “bone-in-bone” appearance, and “sandwich” vertebrae; long bones may look like Erlenmeyer flasks at the ends. CT or MRI of the skull base can show narrowed optic and auditory canals; imaging helps plan surgery if decompression is considered. DEXA shows very high bone density but does not reflect bone strength in this disease. NCBI

Non-pharmacological treatments (therapies & other measures)

1. Allogeneic HSCT (hematopoietic stem cell transplantation)
   What & purpose: Replace the child’s blood-forming system with healthy donor stem cells that can make normal osteoclasts. Mechanism: New donor-derived precursors express normal RANK, restoring osteoclast formation and bone resorption. Why it matters: In TNFRSF11A-deficient ARO7, HSCT has repeatedly rescued the phenotype and is regarded as the only curative option; main post-HSCT issue is transient hypercalcemia as bones remodel. PubMed+1

2. Early referral to a specialized transplant center
   Purpose: Optimize timing before irreversible optic nerve damage or severe marrow failure. Mechanism: Coordinated evaluations (HLA typing, donor search, infection control, nutrition) improve transplant readiness and outcomes. Evidence: Outcomes have improved markedly with modern conditioning and supportive care; timing matters. The Journal of Experimental Biology

3. Infection prevention bundle
   Purpose: Reduce life-threatening infections before/after HSCT in children with marrow crowding and sometimes low antibodies. Mechanism: Strict hygiene, caregiver education, prompt fever protocols, and dental/ENT care reduce bacterial load; targeted antimicrobial prophylaxis is addressed under drugs. Background: Recurrent infections are common in ARO; structured prevention lowers risk. NCBI

4. Transfusion support
   Purpose: Treat anemia and thrombocytopenia from marrow crowding. Mechanism: Packed RBCs and platelets stabilize oxygen delivery and bleeding risk until HSCT restores marrow space. Evidence: Standard supportive care in malignant/infantile osteopetrosis pending or around HSCT. ASH Publications

5. Ophthalmology care & low-vision supports
   Purpose: Protect vision threatened by optic canal narrowing. Mechanism: Serial exams, visual aids, and timely surgical consultation if compression progresses (see surgeries). Evidence: Cranial nerve compression is a hallmark of severe osteopetrosis; early specialty input preserves function when possible. MedlinePlus

6. Audiology & speech-language support
   Purpose: Address conductive or sensorineural hearing loss and speech delay from skull base sclerosis. Mechanism: Early screening, hearing aids if needed, and therapy for communication skills. Evidence: Cranial nerve entrapment frequently affects hearing in ARO. MedlinePlus

7. Physiotherapy & safe mobility training
   Purpose: Improve motor skills without fractures. Mechanism: Low-impact strengthening, balance training, home fall-proofing, and assistive devices prevent injuries in brittle, dense bones. Evidence: Clinically standard in osteopetrosis management to reduce falls and deconditioning. The Journal of Experimental Biology

8. Nutritional optimization with careful calcium/vitamin D balance
   Purpose: Maintain growth while avoiding excessive calcium load. Mechanism: Dietitian-guided energy/protein intake; avoid megadose vitamin D unless prescribed; after HSCT, monitor for hypercalcemia during skeletal remodeling. Evidence/guidance: Expert group advises against high-dose calcitriol in osteopetrosis; hypercalcemia is a known post-HSCT risk. OUP Academic+1

9. Dental prevention program
   Purpose: Reduce tooth eruption problems, caries, and osteomyelitis risk in sclerotic jaws. Mechanism: Fluoride, hygiene, antibacterial rinses, and meticulous procedural planning when extractions are unavoidable. Evidence: Dental/ENT complications common in osteopetrosis; prevention averts infections. The Journal of Experimental Biology

10. Vaccination planning
    Purpose: Maximize vaccine-preventable disease protection before immunosuppression. Mechanism: Complete inactivated vaccines; time live vaccines appropriately relative to HSCT. Evidence: Standard HSCT preparation improves infectious outcomes. The Journal of Experimental Biology

11. Endocrine & mineral monitoring
    Purpose: Detect hypocalcemia (pre-HSCT) and hypercalcemia (post-HSCT remodeling); track vitamin D and PTH. Mechanism: Regular labs and ultrasound screening for nephrocalcinosis if on calcitriol or after HSCT. Evidence: Long-term monitoring recommendations highlighted in contemporary reviews. Medscape

12. Genetic counseling for family planning
    Purpose: Explain autosomal-recessive inheritance (25% recurrence risk), options for prenatal or preimplantation testing. Mechanism: Targeted sequencing of TNFRSF11A variant(s). Evidence: GTR/OMIM describe ARO7 genetics and heterogeneity within ARO. NCBI

---

Drug treatments

Important: Only interferon gamma-1b carries a specific U.S. indication related to severe malignant osteopetrosis. Most other medicines below support HSCT or infection prevention/treatment.

1. Interferon-γ1b (Actimmune®)
   Class/purpose: Immunomodulator approved to delay time to disease progression in severe malignant osteopetrosis (SMO); sometimes used as a bridge to HSCT. Mechanism: Can stimulate osteoclast activation and host defense. Dose/monitoring: Labelled subcutaneous regimens; monitor CBC and LFTs; risks include cytopenias and hepatic toxicity. Evidence: FDA label & orphan approval specify SMO indication; clinical effect is disease-modifying but not curative. FDA Access Data+2FDA Access Data+2

2. Treosulfan (Grafapex®) + Fludarabine (conditioning for HSCT)
   Class/purpose: Alkylator + antimetabolite used as a preparative regimen before allogeneic HSCT. Mechanism: Myeloablation/immunosuppression to permit donor cell engraftment. Dose: Treosulfan 10 g/m² IV daily ×3 (Days –4 to –2) with fludarabine per label; adjust per center protocol. Key risks: Prolonged myelosuppression, infections; renal/hepatic dose considerations. Evidence: 2025 FDA label for Grafapex; fludarabine FDA labels. FDA Access Data+1

3. Busulfan (Busulfex®) – alternative/adjunct conditioning
   Class/purpose: Alkylating agent used in many HSCT regimens. Mechanism: Myeloablation to clear marrow space and suppress host immunity. Dose: Weight- and PK-guided IV dosing per pediatric/adult label; requires therapeutic drug monitoring. Risks: Hepatic veno-occlusive disease, seizures (prophylaxis often used), profound cytopenias. Evidence: FDA labels and pediatric supplement. FDA Access Data+2FDA Access Data+2

4. Cyclophosphamide – conditioning/backbone immunosuppression
   Class/purpose: Alkylating agent frequently combined with busulfan/thiotepa. Mechanism: Cytotoxic immunosuppression facilitating engraftment. Risks: Hemorrhagic cystitis (preventive hydration/mesna), infertility, infections. Evidence: FDA injectable labels. FDA Access Data+1

5. Thiotepa (Tepadina® / Tepylute®) – conditioning adjunct
   Class/purpose: Alkylator added to reduce graft rejection risk alongside busulfan/cyclophosphamide. Mechanism: Additional myeloimmuno-ablation. Risks: Severe marrow suppression; mucositis; neurotoxicity at high exposure. Evidence: FDA approval/labels. FDA Access Data+1

6. Acyclovir (Zovirax®) – HSV/VZV prophylaxis or treatment
   Class/purpose: Antiviral to prevent/treat herpesvirus infections around HSCT. Mechanism: Viral DNA polymerase inhibition. Dosing: Per label (IV or PO) adjusted for renal function. Risks: Nephrotoxicity, neurotoxicity if overdosed or in renal impairment. Evidence: FDA labels. FDA Access Data+1

7. Fluconazole (Diflucan®) – Candida prophylaxis/treatment
   Class/purpose: Azole antifungal widely used during neutropenia. Mechanism: Ergosterol synthesis inhibition. Dose: Pediatric/adult dosing per label; check interactions (QT prolongation). Evidence: Recent FDA labels. FDA Access Data+1

8. Posaconazole (Noxafil®) – mold-active prophylaxis (selected cases)
   Class/purpose: Broad-spectrum azole for high-risk patients during profound neutropenia or GVHD therapy. Mechanism: Ergosterol synthesis inhibition with anti-Aspergillus activity. Dose: Delayed-release tablets or suspension per label; monitor levels/interactions. Evidence: FDA labels. FDA Access Data+1

9. Trimethoprim-Sulfamethoxazole (Bactrim®) – Pneumocystis prophylaxis
   Class/purpose: Standard prophylaxis post-HSCT (as counts allow). Mechanism: Folate pathway blockade in microbes. Dose: Intermittent dosing per label/protocols; monitor for cytopenias/allergy. Evidence: FDA labels. FDA Access Data+1

10. Immune globulin (IVIG; e.g., Gammagard®)
    Class/purpose: Replacement for significant hypogammaglobulinemia and recurrent infections. Mechanism: Provides pooled IgG antibodies; reduces serious bacterial infections. Dose: Weight-based IV regimens; watch for aseptic meningitis, thrombosis risk. Evidence: FDA product pages/package inserts. U.S. Food and Drug Administration+1

Notes on calcitriol: Very high-dose calcitriol can induce osteoclast-like activity and showed historic, short-term improvements, but current expert guidance advises against high-dose calcitriol in osteopetrosis, and it is not FDA-approved for this indication. If considered, it must be specialist-supervised with tight calcium/renal monitoring. New England Journal of Medicine+1

---

Dietary molecular supplements

1. Balanced protein-energy supplements to support growth and wound healing; avoid calcium-fortified products in the peri-transplant window if hypercalcemia risk. Function/mechanism: Maintain positive nitrogen balance and micronutrients needed for marrow recovery. The Journal of Experimental Biology
2. Standard-dose vitamin D (physiologic, not high-dose calcitriol) only if deficient; mechanism: maintain bone/mineral homeostasis and immune function; strict lab monitoring to avoid hypercalcemia, especially post-HSCT. Medscape
3. Omega-3 fatty acids for cardiometabolic support and anti-inflammatory effects; may aid appetite and reduce inflammation during recovery (avoid around procedures if bleeding risk). The Journal of Experimental Biology
4. Probiotics (center-specific) sometimes used after neutropenia resolves to help gut recovery; avoid during profound immunosuppression. The Journal of Experimental Biology
5. Multivitamin without excess minerals, ensuring folate and B-complex support hematopoiesis while avoiding high calcium loads. Medscape

---

Immune-booster / regenerative / stem-cell–related medicines

1. G-CSF (filgrastim) after HSCT to speed neutrophil recovery when indicated; mechanism: stimulates marrow neutrophil production (institutional protocols vary; FDA-approved for neutropenia). The Journal of Experimental Biology
2. Erythropoiesis-stimulating agents in selected post-HSCT anemia scenarios when transfusion avoidance is desired; mechanism: stimulate RBC production (individualized). The Journal of Experimental Biology
3. Mesna + hydration (with cyclophosphamide regimens) to protect the bladder and reduce hemorrhagic cystitis—supporting the safety of conditioning phases that make HSCT possible. FDA Access Data

---

Surgeries & procedures

1. Optic canal decompression: To relieve optic nerve compression threatening vision. Done by neurosurgery/ENT when progressive visual loss is documented and HSCT timing cannot prevent further damage. MedlinePlus
2. CSF shunt or cranial decompression (selected cases): For raised intracranial pressure from skull thickening; goal is symptom relief and optic nerve protection. Orpha.net
3. Dental/ENT surgical management: Drainage of osteomyelitis, careful extractions with antibiotics; aim is to eradicate infection sources that imperil HSCT. The Journal of Experimental Biology

---

Practical preventions

1. Fast track to HSCT evaluation in proven ARO7. PubMed

2. Infection control at home (hand hygiene, mask use during outbreaks). NCBI

3. Vaccinations timed before immunosuppression. The Journal of Experimental Biology

4. Fall-proofing and safe mobility training to prevent fractures. The Journal of Experimental Biology

5. Dental prevention and early treatment of oral infections. The Journal of Experimental Biology

6. Regular eye/hearing checks for early nerve compression signs. MedlinePlus

7. Nutrition checks with avoidance of excessive calcium/vitamin D unless prescribed. OUP Academic

8. Household education on fever action plans and when to seek emergency care. The Journal of Experimental Biology

9. Medication review to avoid drug interactions with azoles and chemo agents. FDA Access Data

10. Long-term labs (Ca/P, vitamin D, PTH, CBC) and renal ultrasound per risk. Medscape

---

When to see doctors urgently

Seek urgent care for fever, breathing trouble, lethargy, seizures, sudden vision/hearing changes, uncontrolled pain, unusual bleeding/bruising, or less wet diapers/reduced urination (possible dehydration or renal issues). Children on calcitriol or immediately after HSCT also need prompt review for vomiting, dehydration, confusion, or arrhythmia, which can signal hypercalcemia. ScienceDirect+1

---

What to eat and what to avoid

Eat: Regular meals rich in protein (eggs, fish, legumes), fruits/vegetables for vitamins, and whole grains for energy. Adequate fluids help kidney function, especially during antivirals/antifungals. Avoid: Calcium-fortified drinks/supplements unless your team prescribes them; mega-dose vitamin D/calcitriol outside specialist plans; and raw/undercooked foods during neutropenia (food safety rules for HSCT). Why: Prevent nutrient deficits while minimizing hypercalcemia and infection risk during treatment. OUP Academic+1

---

FAQs

1) Is ARO7 curable?
Yes—HSCT can restore osteoclasts and cure the bone disease in TNFRSF11A deficiency; timing matters. PubMed

2) Why are the bones both hard and brittle?
Because old bone isn’t removed (no osteoclasts), the skeleton becomes dense but poorly remodeled—so it breaks easily. PMC

3) What makes ARO7 different from RANKL deficiency?
Both are osteoclast-poor, but RANK (TNFRSF11A) deficiency is HSCT-responsive, while RANKL (TNFSF11) deficiency is not. PMC

4) Why do some children have low antibodies?
RANK signaling also influences the immune system, so some patients develop hypogammaglobulinemia. PubMed

5) What is the main medical drug specifically approved for this disease?
Interferon-γ1b is FDA-approved to delay progression of severe malignant osteopetrosis. FDA Access Data

6) Does interferon-γ1b replace HSCT?
No. It may slow progression but does not cure ARO7. HSCT is the curative path. FDA Access Data+1

7) Why avoid high-dose calcitriol?
Old case reports showed activity, but modern guidelines advise against high-dose calcitriol in osteopetrosis due to limited benefit and hypercalcemia risk. OUP Academic

8) What is the biggest risk after successful HSCT?
During bone remodeling, high calcium can occur; teams monitor and manage it. Infection risk is also high until immune reconstitution. ScienceDirect

9) How are eye and ear problems handled?
Frequent checks; if compression threatens function, surgeons may decompress the affected canal/nerve. MedlinePlus

10) Can ARO7 be detected before birth in future pregnancies?
Yes—genetic counseling enables targeted prenatal or preimplantation testing. NCBI

11) What labs are followed long-term?
CBC, calcium/phosphate, 25-OH-vitamin D, PTH, and kidney ultrasound if on vitamin D analogs or after HSCT. Medscape

12) Why so many infection medicines around HSCT?
Conditioning wipes out immune cells, so antivirals, antifungals, and Pneumocystis prophylaxis are essential. FDA Access Data+2FDA Access Data+2

13) What about bone pain?
Use standard pediatric analgesic plans (acetaminophen first-line) and physiotherapy, while avoiding NSAIDs if platelets are very low—individualize with your team. The Journal of Experimental Biology

14) Do adults get ARO7?
ARO7 is classically infantile and severe; adult-onset osteopetroses are usually different genes/phenotypes. The Journal of Experimental Biology

15) What does the RANK gene normally do?
TNFRSF11A (RANK) tells osteoclast precursors to mature; without it, osteoclasts don’t form and bone can’t remodel. MedlinePlus

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.